Erectile preservation following radical prostatectomy

Therapeutic Advances in Urology

Volumn 3, Issue 1, 2011, Pages 35-46

  Segal, Robert ^a   Burnett, Arthur L ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

erectile dysfunction; penile rehabilitation; prostate cancer; radical prostatectomy

Indexed keywords

ERYTHROPOIETIN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; SILDENAFIL; VARDENAFIL;

CLINICAL ASSESSMENT; DATA ANALYSIS; DATA BASE; DRUG MEGADOSE; ERECTILE DYSFUNCTION; GENE THERAPY; HUMAN; INFORMATION RETRIEVAL; MEDICAL RECORD; MEDLINE; METHODOLOGY; PENIS ERECTION; PENIS PROSTHESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REHABILITATION; REVIEW; SUPPOSITORY; VACUUM;

EID: 79959276588     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287211400492     Document Type: Review

References (69)

1. Allaf M.E. Hoke A. Burnett A.L. (2005) Erythropoietin promotes the recovery of erectile function following cavernous nerve injury. J Urol 174: 2060–2064.
2. Arai Y. Okubo K. Aoki Y. Maekawa S. Okada T. Maeda H. (1999) Patient-reported quality of life after radical prostatectomy for prostate cancer. Int J Urol 6: 78–86.
3. Bakircioglu M.E. Lin C.S. Fan P. Sievert K.D. Kan Y.W. Lue T.F. (2001) The effect of adeno-associated virus mediated brain derived neurotrophic factor in an animal model of neurogenic impotence. J Urol 165: 2103–2109.
4. Bannowsky A. Schulze H. van der Horst C. Hautmann S. Junemann K.P. (2008) Recovery of erectile function after nerve-sparing radical prostatectomy: Improvement with nightly low-dose sildenafil. BJU Int 101: 1279–1283.
5. Bella A.J. Perelman M.A. Brant W.O. Lue T.F. (2007) Peyronie–s Disease. J Sex Med 4: 1527–1538.
6. Bill-Axelson A. Holmberg L. Filén F. Ruutu M. Garmo H. Busch C. (2008) Scandinavian Prostate Cancer Group Study Number 4. Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100: 1144–1154.
7. Brines M.L. Ghezzi P. Keenan S. Agnello D. de Lanerolle N.C. Cerami C. (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97: 10526–10531.
8. Burnett A.L. (2005) Erectile dysfunction following radical prostatectomy. JAMA 293: 2648–2653.
9. Burnett A.L. Allaf M.E. Bivalacqua T.J. (2008) Erythropoietin promotes erection recovery after nerve-sparing radical retropubic prostatectomy: A retrospective analysis. J Sex Med 5: 2392–2398.
10. Campana W.M. Myers R.R. (2001) Erythropoietin and erythropoietin receptors in the peripheral nervous system: Changes after nerve injury. FASEB J 15: 1804–1806.
11. Carrier S. Zvara P. Nunes L. Kour N.W. Rehman J. Lue T.F. (1995) Regeneration of nitric oxide synthase-containing nerves after cavernous nerve neurotomy in the rat. J Urol 169: 1722–1727.
12. Celik M. Gökmen N. Erbayraktar S. Akhisaroglu M. Konakc S. Ulukus C. (2002) Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 99: 2258–2263.
13. Ciaro J. de Aboim J. Maringolo M. Andredo E. Agular W. Noguera M. (2001) Intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: An observational study. Sao Paulo Med J 119: 135–137.
14. Costabile R.A. Spevak M. Fishman I.J. Govier F.E. Hellstrom W.J.G. Shabsigh R. (1998) Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 160: 1325–1328.
15. Ehrenreich H. Hasselblatt M. Dembowski C. Cepek L. Lewczuk P. Stiefel M. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8: 495–505.
16. Erbayraktar S. Grasso G. Sfacteria A. Xie Q.W. Coleman T. Kreilgaard M. (2003) Erythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A 100: 6741–6746.
17. Ferrini M.G. Davila H.H. Kovanecz I. Sanchez S.P. Gonzalez-Cadavid N.F. Rajfer J. (2006) Vardenafil prevents fibrosis and loss of corporeal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 68: 429–435.
18. García-Cardoso J. Vela R. Mahillo E. Mateos-Cáceres P.J. Modrego J. Macaya C. (2010) Increased cyclic guanosine monophosphate production and endothelial nitric oxide synthase level in mononuclear cells from sildenafil citrate-treated patients with erectile dysfunction. Int J Impot Res 22: 68–76.
19. Hassan A. El-Hadidy M. El-Deeck B.S. Mostafa T. (2008) Couple satisfaction to different therapeutic modalities for organic erectile dysfunction. J Sex Med 5: 2381–2391.
20. Hatzimouraditis K. Burnett A.L. Haztichristou D. McCullough A.R. Montorsi F. Mulhall J.P. (2009) Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: A critical analysis of the basic science rationale and clinical application. Eur Urol 55: 334–347.
21. Holmberg L. Bill-Axelson A. Helgesen F. Salo J.O. Folmerz P. Häggman M. (2002) A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347: 781–789.
22. Hu J.C. Gu X. Lipsitz L.R. Barry M.J. D–Amico A.V. Weinberg A.C. (2009) Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 302: 1557–1564.
23. Hu J.C. Hevelone N.D. Ferreira M.D. Lipsitz S.R. Choueiri T.K. Sanda M.G. (2008a) Patterns of care for radical prostatectomy in the United States from 2003–2005. J Urol 180: 1969–1974.
24. Hu J.C. Wang Q. Pashos C.L. Lipsitz S.R. Keating N.L. (2008b) Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol 26: 2278–2284.
25. Iacono F. Gianella R. Somma P. Manno G. Fusco F. Mirone V. (2005) Histological alterations in cavernous tissue after radical prostatectomy. J Urol 173: 1673–1676.
26. Jemal A. Siegel R. Ward E. Hao Y. Xu J. Thun M.J. (2009) Cancer statistics 2009. CA Cancer J Clin 2009 59: 225–249.
27. Kato R. Wolfe D. Coyle C.H. Huang S. Wechuck J.B. Goins W.F. (2007) Herpes simplex virus vector-mediated delivery of glial cell line-derived neurotrophic factor rescues erectile dysfunction following cavernous nerve injury. Gene Ther 14: 1344–1352.
28. Kato R. Wolfe D. Coyle C.H. Wechuck J.B. Tyagi P. Tsukamoto T. (2009) Herpes simplex virus vector-mediated delivery of neurturin rescues erectile dysfunction of cavernous nerve injury. Gene Ther 16: 26–33.
29. Kendirci M. Teloken P.E. Champion H.C. Hellstrom W.J.G. Bivalacqua T.J. (2006) Gene therapy for erectile dysfunction: Fact or fiction? Eur Urol 50: 1208–1222.
30. Kohler T.S. Pedro R. Hendlin K. Utz W. Ugarte R. Reddy P. (2007) A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int 100: 858–862.
31. Koul D. Dhar S. Chen-Scarabelli C. Guglin M. Scarabelli T.M. (2007) Erythropoietin: New horizon in cardiovascular medicine. Recent Pat Cardiovasc Drug Discov 2: 5–12.
32. Kovanecz I. Rambhatla A. Ferrini M. Vernet D. Sanchez S. Rajfer J. (2008a) Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. Int J Impot Res 20: 202–212.
33. Kovanecz I. Rambhatla A. Ferrini M.G. Vernet D. Sanchez S. Rajfer J. (2008b) Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int 101: 203–210.
34. Lane B.R. Abouassaly R. Angermeier K.W. Montague D.K. (2007) Three-piece inflatable penile prostheses can be safely implanted after radical prostatectomy through a transverse scrotal incision. Urology 70: 539–542.
35. Lehrfeld T. Lee D.I. (2009) The role of vacuum erection devices in penile rehabilitation after radical prostatectomy. Int J Impot Res 21: 158–164.
36. Leungwattanakij S. Bivalacqua T.J. Usta M.F. Yang D.Y. Hyun J.S. Champion H.C. (2003) Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl 24: 239–245.
37. Litwin M.S. Flanders S.C. Pasta D.J. Stoddard M.L. Lubeck D.P. Henning J.M. (1999) Sexual function and bother after radical prostatectomy or radiation for prostate cancer: Multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 54: 503–508.
38. Liu T. Allaf M.E. Lagoda G. Burnett A.L. (2007) Erythropoietin receptor expression in the human urogential tract: immunolocalization in the prostate, neurovascular bundle and penis. BJU Int 100: 1103–1106.
39. Lowrance W.T. Elkin E.B. Jacks L.M. Yee D.S. Jang T.L. Laudone V.P. (2010) Comparative effectiveness of prostate cancer surgical treatments: A population based analysis of postoperative outcomes. J Urol 183: 1366–1372.
40. Marti H.H. Wenger R.H. Rivas L.A. Straumann U. Digicaylioglu M. Henn V. (1996) Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 8: 666–676.
41. McCullough A.R. Hellstrom W.G. Wang R. Lepor H. Wagner K.R. Engel J.D. (2010) Recovery of erectile function after nerve-sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. J Urol 183: 2451–2456.
42. Melman A. Bar-Chama N. McCullough A. Davies K. Christ G. (2005) The first human trial for gene transfer therapy for the treatment of erectile dysfunction: Preliminary results. Eur Urol 48: 314–318.
43. Montorsi F. Brock G. Lee J. Shapiro J. Van Poppel H. Graefen M. (2008) Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 54: 924–931.
44. Montorsi F. Guazzoni G. Strambi L.F. Da Pozzo L.F. Nava L. Barbieri L. (1997) Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: Results of a prospective, randomized trial. J Urol 158: 1408–1410.
45. Montorsi F. Padma Nathan H. McCullough A. Brock G.B. Broderick G. Ahuja S. (2004) Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: A randomized, double-blind, placebo controlled trial. J Urol 172: 1036–1041.
46. Mooreland R.B. (1998) Is there a role of hypoxemia in penile fibrosis: A viewpoint presented to the Society for the Study of Impotence. Int J Impot Res 10: 113–120.
47. Mulhall J.P. Morgentaler A. (2007) Penile rehabilitation should become the norm for radical prostatectomy patients. J Sex Med 4: 538–543.
48. Mulhall J.P. Slovick R. Hotaling J. Aviv N. Valenzuela R. Waters W.B. (2002) Erectile dysfunction after radical prostatectomy: Hemodynamic profiles and their correlation with the recovery of erectile function. J Urol 167: 1371–1375.
49. Muller A. Tal R. Donohue J.F. Akin-Olugbade Y. Kobylarz K. Paduch D. (2008) The effect of hyperbaric oxygen therapy on erectile function recovery in a rat cavernous nerve injury model. J Sex Med 5: 562–570.
50. Mydlo J.H. Viterbo R. Crispen P. (2005) Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. BJU Int 95: 843–846.
51. Nandipati K. Raina R. Agarwal A. Zippe C.D. (2006) Early combination therapy: Intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res 18: 446–451.
52. Nehra A. Grantmyre J. Nadel A. Thibonnier M. Brock G. (2005) Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J Urol 173: 2067–2071.
53. Padma-Nathan H. Hellstrom W.J. Kaiser F.E. Labasky R.F. Lue T.F. Nolten W. (1997) Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 336: 1–7.
54. Padma-Nathan H. McCullough A.R. Levine L.A. Lipshultz L.I. Siegel R. Montorsi F. (2008) Randomized, double-blind, placebo-controlled study of post-operative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 20: 479–486.
55. Raina R. Agarwal A. Allamaneni S.S.R. Lakin M.M. Zippe C.D. (2005a) Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology 65: 360–364.
56. Raina R. Agarwal A. Ausmundson S. Lakin M. Nandipati K.C. Montague D.K. (2006) Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res 18: 77–81.
57. Raina R. Lakin M.M. Thukral M. Agarwal A. Ausmundson S. Montague D.K. (2003) Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res 15: 318–322.
58. Raina R. Nandipati K.C. Agarwal A. Mansour D. Kaelber D.C. Zippe C.D. (2005b) Combination therapy: Medicated urethral system for erection enhances sexual satisfaction in sildenafil citrate failure following nerve-sparing radical prostatectomy. J Androl 26: 757–760.
59. Raina R. Pahlajani G. Agarwal A. Zippe C.D. (2007) The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. BJU Int 100: 1317–1321.
60. Ramsawh H.J. Morgentaler A. Covino N. Barlow D.H. DeWolf W.C. (2005) Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy. J Urol 174: 1395–1398.
61. Rogers C.G. Trock B.P. Walsh P.C. (2004) Preservation of accessory pudendal arteries during radical retropubic prostatectomy: Surgical technique and results. Urology 64: 148–151.
62. Salonia A. Gallina A. Zanni G. Briganti A. Deho F. Sacca A. (2008) Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. Eur Urol 53: 564–570.
63. Stephenson R.A. Mori M. Hsieh Y. Beer T.M. Stanford J.L. Gilliland F.D. (2005) Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: Patient reported use and outcomes from the surveillance, epidemiology, and end results prostate cancer outcomes study. J Urol 174: 646–650.
64. Tal R. Heck M. Teloken P. Siegrist T. Nelson C.J. Mulhall J.P. (2010) Peyronie–s disease following radical prostatectomy: Incidence and predictors. J Sex Med 7: 1254–1261.
65. User H.M. Hairston J.H. Zelner D.J. McKenna K.E. McVary K.T. (2003) Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol 169: 1175–1179.
66. Vignozzi L. Filippi S. Morelli A. Marini M. Chavalmane A. Fibbi B. (2009) Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism. J Sex Med 6: 1270–1283.
67. Walsh P.C. Donker P.J. (1982) Impotence following radical prostatectomy: Insight into etiology and prevention. J Urol 128: 492–497.
68. Walz J. Burnett A.L. Costello A.J. Eastham J.A. Graefen M. Guillonneau B. (2010) A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Eur Urol 57: 179–192.
69. Yoshimura N. Kato R. Chancellor M.B. Nelson J.B. Glorioso J.C. (2010) Gene therapy as future treatment of erectile dysfunction. Expert Opin Biol Ther 10: 1–10.